Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function
First Claim
1. A composition for preserving the viability of photoreceptor cells, preserving the viability of retinal pigment epithelial cells, or preserving or improving visual function in an eye of a subject with retinal detachment, the composition comprising:
- a pharmaceutically acceptable carrier, a necrostatin and an apoptosis inhibitor,wherein the apoptosis inhibitor is selected from the group consisting of a pan-caspase inhibitor, a caspase-1 inhibitor, a caspase-3 inhibitor, a caspase-8 inhibitor, and a caspase-9 inhibitor, andwherein the necrostatin is selected from the group consisting of;
(i) a Nec-1 related compound of Formula I;
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
-
Citations
12 Claims
-
1. A composition for preserving the viability of photoreceptor cells, preserving the viability of retinal pigment epithelial cells, or preserving or improving visual function in an eye of a subject with retinal detachment, the composition comprising:
- a pharmaceutically acceptable carrier, a necrostatin and an apoptosis inhibitor,
wherein the apoptosis inhibitor is selected from the group consisting of a pan-caspase inhibitor, a caspase-1 inhibitor, a caspase-3 inhibitor, a caspase-8 inhibitor, and a caspase-9 inhibitor, and wherein the necrostatin is selected from the group consisting of; (i) a Nec-1 related compound of Formula I; - View Dependent Claims (2, 3, 4, 5, 6, 7)
- a pharmaceutically acceptable carrier, a necrostatin and an apoptosis inhibitor,
-
8. A pharmaceutical composition formulated for intraocular administration to an eye of a subject with an ocular condition, the composition comprising a pharmaceutically acceptable carrier, a necrostatin, and an apoptosis inhibitor,
wherein the composition is formulated to provide a final concentration of the necrostatin in the eye in the range from about 150 μ - M to about 1000 μ
M,wherein the composition is formulated to provide a final concentration of the apoptosis inhibitor in the range from about 150 μ
M to about 500 μ
M,wherein the apoptosis inhibitor is selected from the group consisting of a pan-caspase inhibitor, a caspase-1 inhibitor, a caspase-3 inhibitor, a caspase-8 inhibitor, and a caspase-9 inhibitor, and wherein the necrostatin is selected from the group consisting of; (i) a Nec-1 related compound of Formula I; - View Dependent Claims (9, 10, 11, 12)
- M to about 1000 μ
Specification